A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcome
- 1k Downloads
The article entitled “Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report” provided an interesting perspective on the onset of insulin-dependent diabetes following anti-programmed cell death therapy . While several recent reports cite the incidence of diabetes onset, little is mentioned on outcome or clinical course over time. Here we present a case of pembrolizumab-induced insulin-dependent diabetes, with insight on the clinical outcome following discontinuation of the offending agent.
Here we present a 58-year-old male, diagnosed with a 2.1-mm thick, Clark Level IV, non-ulcerated, cutaneous melanoma of the left upper arm in 2000. He underwent a wide excision and left axillary lymph node sampling, which revealed one of three lymph nodes to be involved. He was treated with interferon alpha 2B as adjuvant therapy for 1 year. In 2012, imaging revealed a right upper lobe lung nodule, left upper paramediastinal mass and lymphadenopathy in...
KeywordsIpilimumab Vemurafenib Dabrafenib Axillary Lymph Node Sampling Harbor BRAF V600E
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 2.Mekinist (trametinib) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation (2015) Google Scholar
- 3.Tafinlar (dabrafenib) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation (2015)Google Scholar
- 4.Pembrolizumab (keytruda) [package insert]. Whitehouse Station, NJ: Merk & Co., Inc. (2015)Google Scholar
- 5.Keytruda (pembrolizumab) [package insert]. Merck & Co., Inc., Whitehouse Station, NJ (2014)Google Scholar